136 related articles for article (PubMed ID: 21840638)
21. Negotiating the diagnostic uncertainty of contested illnesses: physician practices and paradigms.
Swoboda DA
Health (London); 2008 Oct; 12(4):453-78. PubMed ID: 18818275
[TBL] [Abstract][Full Text] [Related]
22. Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials.
Bhadra P; Petersel D
Expert Opin Pharmacother; 2010 Dec; 11(17):2805-12. PubMed ID: 21039311
[TBL] [Abstract][Full Text] [Related]
23. Fibromyalgia coverage uneven despite recent drug approvals.
Sipkoff M
Manag Care; 2008 Dec; 17(12):9-10. PubMed ID: 19127758
[No Abstract] [Full Text] [Related]
24. Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: an open-label, prospective trial.
Calandre EP; Morillas-Arques P; Rodriguez-Lopez CM; Rico-Villademoros F; Hidalgo J
Pharmacopsychiatry; 2007 Mar; 40(2):68-71. PubMed ID: 17447176
[TBL] [Abstract][Full Text] [Related]
25. [Unreliable about drug industry].
Mikkelsen Y
Tidsskr Nor Laegeforen; 2010 Jul; 130(13):1331; author reply 1331. PubMed ID: 20596108
[No Abstract] [Full Text] [Related]
26. Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.
Chace MJ; Zhang F; Fullerton CA; Huskamp HA; Gilden D; Soumerai SB
J Clin Psychiatry; 2012 Nov; 73(11):1388-94. PubMed ID: 23146199
[TBL] [Abstract][Full Text] [Related]
27. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia.
Zhao Y; Sun P; Watson P; Mitchell B; Swindle R
Pain Pract; 2011; 11(3):204-16. PubMed ID: 20807351
[TBL] [Abstract][Full Text] [Related]
28. Treatment response to pregabalin in fibromyalgia pain: effect of patient baseline characteristics.
Emir B; Murphy TK; Petersel DL; Whalen E
Expert Opin Pharmacother; 2010 Oct; 11(14):2275-80. PubMed ID: 20812879
[TBL] [Abstract][Full Text] [Related]
29. Pharmaceutical industry restructuring and new marketing approaches: enforcement responses.
Mahinka SP; Sanzo KM
Food Drug Law J; 1995; 50(2):313-25. PubMed ID: 10343000
[No Abstract] [Full Text] [Related]
30. [Pregabalin--a neuromodulator for the treatment of neuropathic pain, generalized anxiety disorders and fibromyalgia syndrome].
Nymdelger S; Nieber K
Med Monatsschr Pharm; 2007 Nov; 30(11):396-400. PubMed ID: 18062330
[TBL] [Abstract][Full Text] [Related]
31. Impact of a prior authorization for pregabalin on health plan drug expenditures.
Bazalo G; Weiss RC; Joshi AV
Am J Manag Care; 2010 May; 16(5 Suppl):S154-9. PubMed ID: 20586524
[TBL] [Abstract][Full Text] [Related]
32. Exposure-response analyses of the effects of pregabalin in patients with fibromyalgia using daily pain scores and patient global impression of change.
Byon W; Ouellet D; Chew M; Ito K; Burger P; Pauer L; Zeiher B; Corrigan B
J Clin Pharmacol; 2010 Jul; 50(7):803-15. PubMed ID: 20357295
[TBL] [Abstract][Full Text] [Related]
33. Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin.
Arnold LM; Zlateva G; Sadosky A; Emir B; Whalen E
Pain Med; 2011 Feb; 12(2):260-7. PubMed ID: 21266008
[TBL] [Abstract][Full Text] [Related]
34. Pregabalin: an alpha2-delta (alpha2-delta) ligand for the management of fibromyalgia.
Arnold L; Mease P; Silverman S
Am J Manag Care; 2010 May; 16(5 Suppl):S138-43. PubMed ID: 20586522
[TBL] [Abstract][Full Text] [Related]
35. False Claims Act prosecution did not deter off-label drug use in the case of neurontin.
Kesselheim AS; Darby D; Studdert DM; Glynn R; Levin R; Avorn J
Health Aff (Millwood); 2011 Dec; 30(12):2318-27. PubMed ID: 22147859
[TBL] [Abstract][Full Text] [Related]
36. The drive to reform the FDA gains momentum.
Gatty B
Hosp Formul; 1995 Mar; 30(3):178, 177. PubMed ID: 10141250
[No Abstract] [Full Text] [Related]
37. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development.
Lee VH
Drug Discov Today; 2005 Nov; 10(21):1411-4. PubMed ID: 16243258
[No Abstract] [Full Text] [Related]
38. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.
Tassone DM; Boyce E; Guyer J; Nuzum D
Clin Ther; 2007 Jan; 29(1):26-48. PubMed ID: 17379045
[TBL] [Abstract][Full Text] [Related]
39. The rise of fibromyalgia in 20th-century America.
Grob GN
Perspect Biol Med; 2011; 54(4):417-37. PubMed ID: 22019532
[TBL] [Abstract][Full Text] [Related]
40. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia.
Arnold LM; Russell IJ; Diri EW; Duan WR; Young JP; Sharma U; Martin SA; Barrett JA; Haig G
J Pain; 2008 Sep; 9(9):792-805. PubMed ID: 18524684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
